<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635580</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 046 CT</org_study_id>
    <nct_id>NCT03635580</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS</brief_title>
  <official_title>Phase 2 Study of Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS (Idiopathic Short Stature): a 52-week Multicenter, Open-label, Randomized, Negative Controlled Study Followed by a 52-week Open-label Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Provincial Maternity and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1: To evaluate the safety and efficacy of 0.05mg/kg/d of rhGH (Jintropin®) in the
      treatment of children with idiopathic short stature (ISS) in 52 weeks.

      Phase 2: To evaluate the safety and efficacy of rhGH (Jintropin®) in the treatment of
      children with ISS in 2 years
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ΔHtSDSca (The change of height standard deviation score of chronological age before and after treatment)</measure>
    <time_frame>Baseline, 4,13,26,39,52,65,78,91,104 weeks after initiating treatment, 52 weeks in phase 1; 2 years in phase 2.</time_frame>
    <description>ΔHtSDSca was the difference of HtSDSca before and after treatment, and HtSDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ΔHT (Change of height)</measure>
    <time_frame>Baseline, 4,13,26,39,52,65,78,91,104 weeks after initiating treatment, 52 weeks in phase 1; 2 years in phase 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>△BA/CA (bone age change / chronological age)</measure>
    <time_frame>Baseline, 4,13,26,39,52,65,78,91,104 weeks after initiating treatment, 52 weeks in phase 1; 2 years in phase 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yearly growth velocity</measure>
    <time_frame>Baseline, 4,13,26,39,52,65,78,91,104 weeks after initiating treatment, 52 weeks in phase 1; 2 years in phase 2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔIGF-1 SDS (Change of insulin-like growth factor 1 standard deviation score)</measure>
    <time_frame>Baseline, 4,13,26,39,52,65,78,91,104 weeks after initiating treatment, 52 weeks in phase 1; 2 years in phase 2.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Dwarfism</condition>
  <arm_group>
    <arm_group_label>rhGH/Jintropin AQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative control</intervention_name>
    <description>Untreated-control group</description>
    <arm_group_label>rhGH/Jintropin AQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys are between 4 and 10 years old age and girls are between 4 and 9 years old age;

          -  Height ＜-2.25 SD (Standard deviation) for chronological age;

          -  GH (Growth hormone) peak concentration ≥10.0 ng/mL in GH stimulation tests;

          -  The bone age (BA) ≤chronological age (CA)+6 months;

          -  Prepubertal Status (Tanner Stage I);

          -  Birth weight within the normal range;

          -  Growth hormone treatment-naive;

          -  Participants are willing and able to cooperate to complete scheduled visits, treatment
             plans and laboratory tests and other procedures, to sign informed consent.

        Exclusion Criteria:

          -  Participants with abnormal liver and kidney functions (ALT &gt; upper limit 1.5 times of
             normal value; Cr &gt; upper limit of normal value);

          -  Participants are positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests;

          -  Participants with known highly allergic constitution or allergy to investigational
             product or its excipient;

          -  Participants with systemic chronic disease and immune deficiency;

          -  Participants diagnosed with tumor, or with potential high tumor risks such as tumor
             markers exceed normal range and some other relative information may be excluded from
             the treatment;

          -  Participants with mental disease;

          -  Participants with other types of abnormal growth and development;

               1. Growth hormone deficiency (GHD) (confirmed by GH stimulation test);

               2. Turner syndrome (confirmed by karyotype test of girls);

               3. Noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with
                  skin disease and congenital heart disease, missense mutation of the protein
                  tyrosine phosphatase, non-receptor type 11 (PTPN11) gene on chromosome 12 for
                  half of the participants, for both male and female participants);

               4. Laron syndrome (confirmed by IGF-1 generation test);

               5. Small for gestational age ( the birth height or weight is below the tenth
                  percentile or 2 SD, with catch-up growth uncompleted at 2 years old);

               6. Growth disorders caused by malnutrition or hypothyroidism (thyroid function
                  test).

          -  Participants with impaired glucose regulation (IGR) (including impaired fasting
             glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes;

          -  BMI (Body mass index) ≥22kg/m²;

          -  Congenital skeletal abnormalities or scoliosis, claudication;

          -  Participants who took part in other clinical trials within 3 months;

          -  Participants who received medications which may interfere GH secretion or GH function,
             or other hormones within 3 months (such as sex steroids, glucocorticoids, etc.);

          -  Other conditions which is inappropriate for this study in the opinion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junfen Fu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Hospital of Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Feng</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Children's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Shanxi</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

